Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring
Bruker (NASDAQ: BRKR) has announced a majority investment in RECIPE Chemicals + Instruments GmbH, a Munich-based provider of therapeutic drug monitoring (TDM) and clinical diagnostic kits. RECIPE, with over 60 employees and 2024 revenues exceeding $15 million, will continue operating under Dr. Gernot Wolfram's leadership.
The strategic collaboration enhances Bruker's capabilities in small molecule clinical diagnostic assays through RECIPE's ClinMASS® kits for EVOQ® liquid chromatography systems. The companies are also launching high-throughput, chromatography-free ClinDART® kits for EVOQ-DART TQ⁺ systems.
The new ClinDART platform offers:
- 95% reduction in solvent use
- Lower operational costs
- Increased laboratory productivity
- Flexibility to switch between LC-TQ-MS methods and novel high-throughput workflows
Bruker (NASDAQ: BRKR) ha annunciato un investimento di maggioranza in RECIPE Chemicals + Instruments GmbH, un'azienda con sede a Monaco specializzata in kit per il monitoraggio terapeutico dei farmaci (TDM) e diagnostica clinica. RECIPE, con oltre 60 dipendenti e ricavi per più di 15 milioni di dollari nel 2024, continuerà a operare sotto la guida del Dr. Gernot Wolfram.
La collaborazione strategica potenzia le capacità di Bruker nei saggi diagnostici clinici per piccole molecole grazie ai kit ClinMASS® di RECIPE per i sistemi di cromatografia liquida EVOQ®. Le aziende stanno inoltre lanciando kit ad alto rendimento e senza cromatografia ClinDART® per i sistemi EVOQ-DART TQ⁺.
La nuova piattaforma ClinDART offre:
- Riduzione del 95% nell’uso di solventi
- Costi operativi inferiori
- Aumento della produttività di laboratorio
- Flessibilità nel passaggio tra metodi LC-TQ-MS e nuovi flussi di lavoro ad alto rendimento
Bruker (NASDAQ: BRKR) ha anunciado una inversión mayoritaria en RECIPE Chemicals + Instruments GmbH, un proveedor con sede en Múnich de kits para el monitoreo terapéutico de fármacos (TDM) y diagnóstico clínico. RECIPE, con más de 60 empleados y unos ingresos superiores a 15 millones de dólares en 2024, continuará operando bajo el liderazgo del Dr. Gernot Wolfram.
La colaboración estratégica mejora las capacidades de Bruker en ensayos diagnósticos clínicos de pequeñas moléculas mediante los kits ClinMASS® de RECIPE para sistemas de cromatografía líquida EVOQ®. Las compañías también están lanzando kits ClinDART® de alto rendimiento y sin cromatografía para los sistemas EVOQ-DART TQ⁺.
La nueva plataforma ClinDART ofrece:
- Reducción del 95% en el uso de disolventes
- Menores costos operativos
- Aumento de la productividad del laboratorio
- Flexibilidad para alternar entre métodos LC-TQ-MS y nuevos flujos de trabajo de alto rendimiento
Bruker (NASDAQ: BRKR)는 치료 약물 모니터링(TDM) 및 임상 진단 키트를 제공하는 뮌헨 소재 기업 RECIPE Chemicals + Instruments GmbH에 대한 다수 지분 투자를 발표했습니다. RECIPE는 60명 이상의 직원을 보유하고 있으며 2024년 매출이 1,500만 달러를 초과하며, Gernot Wolfram 박사의 리더십 하에 계속 운영될 예정입니다.
이번 전략적 협력으로 Bruker는 RECIPE의 ClinMASS® 키트를 통한 소분자 임상 진단 분석 능력을 EVOQ® 액체 크로마토그래피 시스템용으로 강화했습니다. 양사는 또한 EVOQ-DART TQ⁺ 시스템용 고처리량 무크로마토그래피 ClinDART® 키트를 출시하고 있습니다.
새로운 ClinDART 플랫폼은 다음과 같은 장점을 제공합니다:
- 용매 사용량 95% 감소
- 운영 비용 절감
- 실험실 생산성 향상
- LC-TQ-MS 방법과 새로운 고처리량 워크플로 간 전환의 유연성
Bruker (NASDAQ : BRKR) a annoncé un investissement majoritaire dans RECIPE Chemicals + Instruments GmbH, un fournisseur basé à Munich de kits de surveillance thérapeutique des médicaments (TDM) et de diagnostic clinique. RECIPE, qui compte plus de 60 employés et dont le chiffre d'affaires 2024 dépasse 15 millions de dollars, continuera d'opérer sous la direction du Dr Gernot Wolfram.
Cette collaboration stratégique renforce les capacités de Bruker dans les tests de diagnostic clinique pour petites molécules grâce aux kits ClinMASS® de RECIPE pour les systèmes de chromatographie liquide EVOQ®. Les entreprises lancent également des kits ClinDART® à haut débit et sans chromatographie pour les systèmes EVOQ-DART TQ⁺.
La nouvelle plateforme ClinDART offre :
- Réduction de 95 % de l'utilisation des solvants
- Coûts opérationnels réduits
- Productivité accrue des laboratoires
- Flexibilité pour passer des méthodes LC-TQ-MS aux nouveaux flux de travail à haut débit
Bruker (NASDAQ: BRKR) hat eine Mehrheitsbeteiligung an der RECIPE Chemicals + Instruments GmbH angekündigt, einem in München ansässigen Anbieter von Therapeutischem Arzneimittelmonitoring (TDM) und klinischen Diagnostik-Kits. RECIPE, mit über 60 Mitarbeitern und einem Umsatz von über 15 Millionen US-Dollar im Jahr 2024, wird weiterhin unter der Leitung von Dr. Gernot Wolfram operieren.
Die strategische Zusammenarbeit erweitert Brukers Fähigkeiten bei klinischen Diagnostik-Assays für kleine Moleküle durch die ClinMASS®-Kits von RECIPE für EVOQ®-Flüssigchromatographiesysteme. Die Unternehmen bringen zudem hochdurchsatzfähige, chromatographiefreie ClinDART®-Kits für EVOQ-DART TQ⁺-Systeme auf den Markt.
Die neue ClinDART-Plattform bietet:
- 95% Reduzierung des Lösungsmittelverbrauchs
- Niedrigere Betriebskosten
- Erhöhte Laborproduktivität
- Flexibilität beim Wechsel zwischen LC-TQ-MS-Methoden und neuartigen Hochdurchsatz-Workflows
- Strategic acquisition of profitable company with $15M+ annual revenue
- Expands clinical diagnostic capabilities with established ClinMASS® product line
- New ClinDART technology reduces operational costs by 95% in solvent usage
- Enhances market position in therapeutic drug monitoring (TDM) sector
- Immediate revenue contribution from existing profitable operations
- Financial terms of acquisition not disclosed
- Only majority stake acquired, not full ownership
Insights
Bruker's majority acquisition of RECIPE represents a strategic vertical integration move that strengthens its position in the clinical mass spectrometry market. RECIPE, with $15+ million in 2024 revenue and a profitable operation, brings immediate value to Bruker's portfolio through its established ClinMASS kits that run on Bruker's EVOQ systems and other vendors' platforms.
The most significant aspect of this deal is the joint development of chromatography-free ClinDART kits, which could substantially disrupt the therapeutic drug monitoring (TDM) market by reducing operational costs and increasing throughput. The claimed 95% reduction in solvent usage translates to substantial consumables cost savings for clinical laboratories, which typically operate under tight budget constraints.
While financial terms weren't disclosed, this acquisition follows Bruker's pattern of targeted investments in specialized companies with complementary technologies. The deal immediately expands Bruker's recurring revenue streams through RECIPE's diagnostic kit sales, which typically provide higher margins and more predictable revenue than instrument sales alone.
This investment positions Bruker to capture more value from the clinical diagnostics workflow by offering both the instruments and the consumable test kits – a classic razor/razor blade business model. The ability to offer flexible systems that can switch between traditional LC-MS methods and higher-throughput chrom-free workflows provides a compelling value proposition that could accelerate adoption in clinical settings where both versatility and efficiency are paramount.
This acquisition addresses a critical pain point in clinical mass spectrometry – the throughput and operational cost limitations of traditional LC-MS/MS methods. RECIPE's novel ClinDART technology eliminates chromatography while maintaining triple-quadrupole selectivity, which solves a technical challenge that has long constrained adoption of mass spectrometry in routine clinical testing.
The technology differentiation is substantial. Current LC-MS/MS methods require skilled operators, extensive sample preparation, and significant time per sample. By removing chromatography while preserving mass spectrometry's specificity through multiple-reaction monitoring (MRM), RECIPE's approach potentially delivers the best of both worlds: the throughput advantage of immunoassays with the selectivity of mass spectrometry.
For therapeutic drug monitoring applications, where precision dosing requires accurate and timely results, this increased throughput could significantly improve patient care by enabling more frequent testing and faster turnaround times. Similarly, for drugs of abuse screening, higher throughput translates to more efficient processing in high-volume testing environments.
The flexibility to run both traditional LC-MS methods and chromatography-free assays on the same platform is particularly valuable for clinical laboratories that need versatility. Rather than forcing an either/or choice, Bruker can now offer a scalable solution that adapts to varying workloads and test requirements. This technological approach could substantially reduce the barrier to entry for mass spectrometry adoption in clinical laboratories that have traditionally relied on alternative methods due to throughput constraints.
Bruker and RECIPE are pioneering the high-throughput ‘chrom-free’ ClinDART triple-quad MS platform for robust and cost-effective therapeutic drug monitoring assays
RECIPE kits for clinical laboratories
Financial details of the transaction were not disclosed. RECIPE has over 60 employees and continues to operate under the leadership of Managing Director Dr. Gernot Wolfram. With more than 40 years of experience, RECIPE is a highly respected, profitable company with 2024 revenues of more than
The majority investment and strategic collaboration immediately enhances Bruker's capabilities in small molecule clinical diagnostic assays with RECIPE’s ClinMASS® kits for Bruker’s EVOQ® liquid chromatography triple-quadrupole mass spectrometers, as well as for LC-TQ-MS systems by other vendors. In addition, the companies are preparing the introduction of high-throughput, chromatography-free (‘chrom-free’) RECIPE ClinDART® kits running on flexible EVOQ-DART TQ⁺ systems that can easily switch between established LC-TQ-MS methods, and the novel high-throughput ClinDART workflows.
In chrom-free mode, the EVOQ-DART TQ⁺ offers higher throughput for multiplex assays without chromatography, while maintaining outstanding sensitivity and quantitation with triple-quad MS selectivity and multiple-reaction monitoring (MRM) capabilities. The ClinDART® platform also improves sustainability with a
"Bruker's majority investment in RECIPE and our planned joint introduction of high-throughput ClinDART® assays represents a significant advancement in clinical mass spectrometry," said Dr. Gernot Wolfram, Managing Director at RECIPE. "Our unique collaboration on chrom-free, triple-quad TDM assays will allow RECIPE to provide clinical laboratories with a powerful new tool that complements our well-regarded ClinMASS® workflows on the EVOQ-DART TQ⁺. The additional high-throughput ClinDART methods reduce operating costs, and accelerate time-to-market for newly developed clinical diagnostics and multiplexed drugs of abuse screening assays."
Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry, added: "We are excited to welcome RECIPE to the Bruker family. This majority investment aligns with our strategic vision for LC-TQ-MS assays, enhanced with novel chrom-free assays based on our proprietary DART® technology to lead in clinical research and regulated TDM markets. The RECIPE ClinMASS and novel ClinDART® assays, combined with LC or chrom-free EVOQ DART-TQ⁺ methods, are expected to offer unparalleled flexibility, throughput and cost-effectiveness."
Juergen Srega, Bruker CALID Group President, commented: “With the increasing importance of triple-quadrupole-based small molecule clinical diagnostics, our strategic collaboration with RECIPE is a pivotal step to democratize fast, efficient and sensitive assays for TDM, drugs of abuse screening and other clinical assays on a high-throughput, chrom-free TQ-MS platform.”
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416762711/en/
Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Source: Bruker Corporation
FAQ
What is the revenue of RECIPE in 2024 that Bruker (BRKR) is acquiring?
How many employees does RECIPE have after Bruker's (BRKR) acquisition?
What are the key benefits of RECIPE's ClinDART platform for Bruker (BRKR)?
Who will lead RECIPE following Bruker's (BRKR) majority investment?
What are the main products RECIPE brings to Bruker's (BRKR) portfolio?
